Novo-Nordisk A/S
NVODividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 26, 2025 | $0.58 | 2025-08-18 | 2025-08-18 |
| April 8, 2025 | $1.14 | 2025-03-31 | 2025-03-31 |
| August 26, 2024 | $0.52 | 2024-08-16 | 2024-08-16 |
| April 2, 2024 | $0.93 | 2024-03-22 | 2024-03-25 |
| August 29, 2023 | $0.88 | 2023-08-18 | 2023-08-21 |
Dividends Summary
- Novo-Nordisk A/S has issued 33 dividend payments over the past 22 years
- The most recent dividend was paid 116 days ago, on August 26, 2025
- The highest dividend payed out to investors during this period was $3.10 per share
- The average dividend paid during this period was $0.95 per share.
Company News
Eli Lilly reported positive Phase 3 trial results for orforglipron, an oral medication that helps maintain weight loss after initial treatment with Wegovy or Zepbound. The study showed participants maintained their weight loss with minimal changes over 52 weeks.
Viking Therapeutics, a biotech company with an oral anti-obesity drug VK2735, is potentially a takeover target in 2026 due to its promising drug pipeline despite some initial safety concerns in clinical trials.
Pfizer is investing heavily in the obesity drug market through a $2.1 billion licensing deal with YaoPharma, hoping to recover revenue lost from declining COVID-19 vaccine sales and improve its struggling stock performance.
The hemophilia inhibitors market is projected to expand significantly between 2025-2035, driven by innovative therapies, increased disease awareness, and advancements in gene therapy treatments for genetic bleeding disorders.
Novo Nordisk and Eli Lilly have both cut prices on their weight-loss drugs Wegovy and Zepbound, respectively, in an apparent price war to attract more customers.
